Skip to main content
AAPL-0.36%MSFT+0.70%NVDA+3.73%GOOGL-1.24%AMZN+0.68%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.62%TSLA+0.87%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+3.96%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.65%AUDUSD-0.57%NZDUSD-0.51%GBPAUD+0.49%GBPNZD+0.46%EURJPY-0.44%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.36%AUDCAD-0.33%GBPHKD+0.32%EURUSD-0.31%AUDCHF-0.30%NZDCAD-0.30%USDCHF+0.29%GBPMXN-0.28%EURAUD+0.26%NZDCHF-0.25%EURGBP-0.24%GBPCHF+0.24%USDCAD+0.23%EURNZD+0.21%GBPJPY-0.19%USDTHB-0.18%GBPCAD+0.16%USDTRY+0.16%USDILS+0.16%USDJPY-0.14%USDCNH-0.10%USDDKK+0.10%EURCNH-0.08%EURSGD-0.07%NZDMXN+0.07%EURCAD-0.07%NZDSGD+0.07%CHFSGD-0.06%GBPUSD-0.05%AUDNOK+0.05%SGDJPY+0.05%AUDNZD-0.05%CADCHF+0.05%USDCOP-0.04%USDMXN+0.03%USDSGD+0.02%AUDSGD+0.01%EURCHF-0.01%USDHKD+0.01%GBPSGD-0.01%USDZAR0.00%USDNOK0.00%PLNJPY0.00%GBPZAR0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURPLN0.00%EURCZK0.00%EURSEK0.00%EURZAR0.00%EURNOK0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%XAUUSD-0.47%GAUUSD-0.46%XNGUSD+0.46%XPTUSD-0.39%GAGUSD-0.36%XAGUSD-0.36%HG1-0.11%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%W10.00%BTCUSD-0.19%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+6.50%XMRUSDT+3.02%DOGEUSD+59.04%LINKUSD+1.44%XLMUSD+2.65%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.27%TONUSD+63.46%SUIUSD+2.10%HBARUSDT+1.13%TAOUSDT+3.44%AAVEUSD+3.57%ONDOUSDT+0.85%ICPUSDT-8.30%DOTUSDT+1.18%WLDUSDT+2.24%ARBUSDT+0.63%INJUSDT+7.34%ATOMUSDT-0.39%STXUSDT+5.51%PYTHUSDT+2.05%TIAUSDT+0.91%FETUSDT+0.61%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.71%OPUSDT-2.36%IOTAUSDT+3.17%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.67%FARTCOINUSDT-1.22%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.29%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%AAPL-0.36%MSFT+0.70%NVDA+3.73%GOOGL-1.24%AMZN+0.68%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.62%TSLA+0.87%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+3.96%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.65%AUDUSD-0.57%NZDUSD-0.51%GBPAUD+0.49%GBPNZD+0.46%EURJPY-0.44%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.36%AUDCAD-0.33%GBPHKD+0.32%EURUSD-0.31%AUDCHF-0.30%NZDCAD-0.30%USDCHF+0.29%GBPMXN-0.28%EURAUD+0.26%NZDCHF-0.25%EURGBP-0.24%GBPCHF+0.24%USDCAD+0.23%EURNZD+0.21%GBPJPY-0.19%USDTHB-0.18%GBPCAD+0.16%USDTRY+0.16%USDILS+0.16%USDJPY-0.14%USDCNH-0.10%USDDKK+0.10%EURCNH-0.08%EURSGD-0.07%NZDMXN+0.07%EURCAD-0.07%NZDSGD+0.07%CHFSGD-0.06%GBPUSD-0.05%AUDNOK+0.05%SGDJPY+0.05%AUDNZD-0.05%CADCHF+0.05%USDCOP-0.04%USDMXN+0.03%USDSGD+0.02%AUDSGD+0.01%EURCHF-0.01%USDHKD+0.01%GBPSGD-0.01%USDZAR0.00%USDNOK0.00%PLNJPY0.00%GBPZAR0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURPLN0.00%EURCZK0.00%EURSEK0.00%EURZAR0.00%EURNOK0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%XAUUSD-0.47%GAUUSD-0.46%XNGUSD+0.46%XPTUSD-0.39%GAGUSD-0.36%XAGUSD-0.36%HG1-0.11%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%W10.00%BTCUSD-0.19%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+6.50%XMRUSDT+3.02%DOGEUSD+59.04%LINKUSD+1.44%XLMUSD+2.65%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.27%TONUSD+63.46%SUIUSD+2.10%HBARUSDT+1.13%TAOUSDT+3.44%AAVEUSD+3.57%ONDOUSDT+0.85%ICPUSDT-8.30%DOTUSDT+1.18%WLDUSDT+2.24%ARBUSDT+0.63%INJUSDT+7.34%ATOMUSDT-0.39%STXUSDT+5.51%PYTHUSDT+2.05%TIAUSDT+0.91%FETUSDT+0.61%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.71%OPUSDT-2.36%IOTAUSDT+3.17%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.67%FARTCOINUSDT-1.22%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.29%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%

China clears Eli Lilly obesity pill

NEWS

November 12, 2026 at 09:22 UTC

3 min read
Unbranded GLP-1 weight-loss pills in blister pack symbolizing LLY obesity drug approval in China

Key Points

  • 01China has approved Eli Lilly (LLY)’s GLP-1 weight-loss pill orforglipron
  • 02Lilly (LLY) is the first to gain approval for a GLP-1 weight-loss pill in China
  • 03Orforglipron is a once-daily oral GLP-1 receptor agonist for weight control
  • 04Lilly (LLY) plans $3 billion of China manufacturing investment over 10 years

China approves Eli Lilly’s orforglipron

China’s medicines regulator has approved Eli Lilly’s weight-loss pill orforglipron, granting marketing authorisation for the once-daily oral treatment for weight management. The approval was announced on November 12, 2026, and makes orforglipron one of the latest GLP-1-based therapies cleared for use in the country’s obesity-treatment market.

With this decision, Eli Lilly becomes the first pharmaceutical company to have a GLP-1-based weight-loss pill approved in China. The move gives the company an early advantage in a segment where major global and local drugmakers are competing to address rising rates of overweight and obesity.

Profile of orforglipron and its use

Orforglipron is a small-molecule, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, marketed as Foundayo in the United States. It mimics the action of the body’s natural GLP-1 hormone, which helps regulate appetite and improve blood glucose control, supporting weight management in eligible patients.

Unlike injectable GLP-1 medications, orforglipron is administered as a daily pill and does not require restrictions on food or water intake around dosing. Novo Nordisk and Eli Lilly both see weight-loss pills as an option for people who may be reluctant to use injectable therapies, although Novo’s oral Wegovy has not been approved in China.

Competitive landscape and market context

Approval of orforglipron positions Eli Lilly ahead of Danish rival Novo Nordisk in China’s GLP-1 weight-loss pill segment. The pill will compete for market share with Lilly’s own once-weekly GLP-1 weight-loss injection and similar injectable products from Novo Nordisk, Pfizer and local firm Innovent Biologics.

China is the world’s second-largest pharmaceutical market, and its National Health Commission has indicated that the proportion of overweight or obese people in the country could exceed 65% by 2030. In this context, GLP-1-based drugs have become a key focus for global and domestic drugmakers seeking to expand their obesity-treatment portfolios.

Regulatory path and investment plans in China

The Chinese approval of orforglipron follows Eli Lilly’s submission of a marketing application to local regulators in late 2025. Lilly was the first to apply for approval of a GLP-1 weight-loss pill in China, supporting its bid to secure an early lead in the category.

In parallel with the regulatory process, Eli Lilly has expanded its manufacturing ambitions in China, outlining a planned investment of $3 billion over the next decade to bolster local production capacity. This is intended to strengthen the company’s position in China’s expanding obesity-treatment market and support supply of products such as orforglipron.

Details on the pricing of orforglipron in China and the timing of its commercial launch have not yet been disclosed. For now, the approval marks a significant step in broadening treatment options for obesity and overweight patients in China, particularly for those preferring oral therapies over injections.

Key Takeaways

  • 01Eli Lilly secures an early-mover position in China’s GLP-1 weight-loss pill segment by being first to gain approval for an oral therapy.
  • 02The once-daily pill format of orforglipron broadens GLP-1 treatment options in China beyond injections, targeting patients who prefer oral medications.
  • 03Lilly’s planned $3 billion manufacturing investment over ten years underlines a long-term commitment to China’s obesity-treatment market and local production capacity.

China clears Eli Lilly obesity pill | Trading Dashboard